Aegera Therapeutics Inc. and Human Genome Sciences, Inc. Conclude Collaboration and License Agreement and Subscription Agreement

Aegera Therapeutics Inc., a privately-held Canadian clinical-stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs, has granted to Human Genome Sciences, Inc. a Collaboration and License Agreement as of December 19, 2007, under which HGS has acquired exclusive worldwide rights (excluding Japan) to develop and commercialize AEG40826 and related backup compounds to be chosen during a three-year research collaboration.

Under the agreement, Human Genome Sciences, Inc. has paid Aegera Therapeutics Inc. an upfront license fee of US$15 million and has made an equity investment of $5 million. Aegera Therapeutics Inc. will be entitled to receive up to $295 million in future development and commercial milestone payments, including a $5 million milestone payment upon US Food & Drug Administration clearance of an IND. Aegera will receive double-digit royalties on net sales in the HGS territory. In North America, Aegera Therapeutics Inc. will have the option to co-promote, under which it will share certain expenses and profits (30 per cent) in lieu of its royalties. Aegera Therapeutics Inc. retains the non-oncology rights to its IAP inhibitors that are not selected for development under this agreement.

Aegera Therapeutics Inc. was represented by Sharon G. Druker (corporate) of Robinson Sheppard Shapiro LLP, and Steven D. Barrett (intellectual property) of Wilmer Cutler Pickering Hale and Dorr LLP. Human Genome Sciences, Inc. was represented by James H. Davis, PhD, General Counsel and Secretary, and Ed Yip, Associate General Counsel (intellectual property) and by Jason Harmon and Michael Hardy of DLA Piper US LLP (corporate).